Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update. Read the press release here: https://lnkd.in/ejpaMwQC

CEO Leonard Mazur states, "The establishment of a permanent J-code marks a critical milestone in supporting patient access to LYMPHIR, providing coding clarity for physicians and facilities who administer LYMPHIR, and facilitating reimbursement.    This achievement is a key step in ensuring that LYMPHIR is accessible to patients with commercial and government insurance (VA, DoD, Medicare) coverage.”   In case you missed it, dive into the press release: https://bit.ly/4aNeA70 #Healthcare #CTCL #OncNews #Oncology

Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for #Medicare and #Medicaid Services. Read the press release here: https://bit.ly/4aNeA70   

Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma. Key takeaways:  • 36.2% ORR • 1.4 month time to response • Median duration of response of 8.9 months • Tolerable safety profile In case you missed it, read more via American Society of Clinical Oncology (ASCO): https://lnkd.in/eQCytMZj #CTCL 

CEO Leonard Mazur shares insights on LYMPHIR's planned commercial launch: “Since LYMPHIR's approval, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing, marketing, reimbursement and sales efforts.   This is a pivotal inflection point as we transition from clinical development to revenue generation. Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including licensing partnerships in key international markets, for which discussions are underway, expanded indications for LYMPHIR, in addition to LYMPHIR's potential as a combination immunotherapy.    Our unwavering goal remains to deliver substantial value to patients, healthcare providers, and shareholders by bringing this innovative cancer treatment to market.” Dive into the press release for more: https://lnkd.in/ePuG6Erx

Citius Pharmaceuticals (Nasdaq: CTXR) Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules. Read the press release here: https://lnkd.in/efq-MJKR

Citius Pharmaceuticals (Nasdaq: CTXR) and Citius Oncology (Nasdaq: CTOR) Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025. Read the press release here: https://lnkd.in/ePuG6Erx #Biopharma #CTCL

The Citius Oncology team was thrilled to meet so many KOLs, physicians and supporters of breakthrough therapies at the #ASH24 conference. Thank you to everyone who stopped by and met with the team!

The Citius team had a productive FDA Type C meeting last week to discuss our Phase 3 Mino-Lok® program and the pathway to approval. Read the press release here: https://lnkd.in/eeXFxWhX

LYMPHIR™ (denileukin diftitox-cxdl or E7777) Combo Shows Promising ORR and CBR in Solid Tumors. A combined regimen of pembrolizumab (Keytruda) and denileukin diftitox-cxdl (E7777; Lymphir) yielded promising preliminary results in a small cohort of patients with recurrent or advanced metastatic solid tumors, early findings from a phase 1 study (NCT05200559) showed. Thank you Cancer Network for covering our news! Read more here: https://lnkd.in/eTQ488a4 #Biopharma